Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies
Background: The EMCOVID project conducted a multi-centre cohort study to investigate the impact of COVID-19 on patients with Multiple Sclerosis (pwMS) receiving disease-modifying therapies (DMTs). The study aimed to evaluate the seroprevalence and persistence of SARS-CoV-2 antibodies in MS patients...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:310697 |
| Acceso en línea: | https://ddd.uab.cat/record/310697 https://dx.doi.org/urn:doi:10.3390/jcm12237243 |
| Access Level: | acceso abierto |
| Palabra clave: | Multiple Sclerosis COVID-19 SARS-CoV-2 DMT Seroprevalence |
| id |
ES_76d70e56cfda3f37b97afde9b4d6579b |
|---|---|
| oai_identifier_str |
oai:ddd.uab.cat:310697 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| dc.title.none.fl_str_mv |
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies A Multi-Centre Study |
| title |
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies |
| spellingShingle |
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies Sancho-Saldaña, Agustín Multiple Sclerosis COVID-19 SARS-CoV-2 DMT Seroprevalence |
| title_short |
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies |
| title_full |
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies |
| title_fullStr |
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies |
| title_full_unstemmed |
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies |
| title_sort |
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies |
| dc.creator.none.fl_str_mv |
Sancho-Saldaña, Agustín Gil Sánchez, Anna|||0000-0002-0738-5578 González-Mingot, Cristina|||0000-0002-6387-8764 Peralta, Silvia Solana, Maria José Torres, Pascual|||0000-0001-7903-3478 Juanes, Alba Quibus, Laura Ruiz, Emilio Sanpedro, Eduardo Quirant, Bibiana|||0000-0002-3875-8074 Martínez Cáceres, Eva María|||0000-0002-6762-8025 Ramo-Tello, Cristina|||0000-0001-8643-5053 Presas Rodríguez, Sílvia|||0000-0001-8545-2476 García Rubio, Sebatián Baron, Beatriz Pardiñas|||0000-0002-3041-9238 Ramió-Torrentà, Lluís|||0000-0002-6999-1004 Sotoca Fernández, Javier|||0000-0003-3400-1434 González-Suárez, Inés|||0000-0002-9897-0771 Eichau Madueño, Sara Prieto, Jose Maria|||0000-0002-8170-0724 Blasco Quilez, Maria Rosario|||0000-0003-2719-4629 Sabín-Muñoz, Julia|||0000-0001-5745-7544 Sánchez López, Antonio José|||0000-0001-7168-6175 Llorens Calatayud, Gloria Calles, Carmen Perez-Sempere, Angel|||0000-0002-0195-2834 Garces, Moises|||0000-0002-1756-5492 Carmona, Olga|||0000-0002-5957-0046 Moral, Ester Hervás, José Vicente Blanco, Yolanda Sola-Valls, Nuria Téllez Lara, Nieves|||0000-0001-8787-2239 Forero, Lucía|||0000-0003-0256-6748 Brieva Ruiz, Luis|||0000-0002-5871-6189 |
| author |
Sancho-Saldaña, Agustín |
| author_facet |
Sancho-Saldaña, Agustín Gil Sánchez, Anna|||0000-0002-0738-5578 González-Mingot, Cristina|||0000-0002-6387-8764 Peralta, Silvia Solana, Maria José Torres, Pascual|||0000-0001-7903-3478 Juanes, Alba Quibus, Laura Ruiz, Emilio Sanpedro, Eduardo Quirant, Bibiana|||0000-0002-3875-8074 Martínez Cáceres, Eva María|||0000-0002-6762-8025 Ramo-Tello, Cristina|||0000-0001-8643-5053 Presas Rodríguez, Sílvia|||0000-0001-8545-2476 García Rubio, Sebatián Baron, Beatriz Pardiñas|||0000-0002-3041-9238 Ramió-Torrentà, Lluís|||0000-0002-6999-1004 Sotoca Fernández, Javier|||0000-0003-3400-1434 González-Suárez, Inés|||0000-0002-9897-0771 Eichau Madueño, Sara Prieto, Jose Maria|||0000-0002-8170-0724 Blasco Quilez, Maria Rosario|||0000-0003-2719-4629 Sabín-Muñoz, Julia|||0000-0001-5745-7544 Sánchez López, Antonio José|||0000-0001-7168-6175 Llorens Calatayud, Gloria Calles, Carmen Perez-Sempere, Angel|||0000-0002-0195-2834 Garces, Moises|||0000-0002-1756-5492 Carmona, Olga|||0000-0002-5957-0046 Moral, Ester Hervás, José Vicente Blanco, Yolanda Sola-Valls, Nuria Téllez Lara, Nieves|||0000-0001-8787-2239 Forero, Lucía|||0000-0003-0256-6748 Brieva Ruiz, Luis|||0000-0002-5871-6189 |
| author_role |
author |
| author2 |
Gil Sánchez, Anna|||0000-0002-0738-5578 González-Mingot, Cristina|||0000-0002-6387-8764 Peralta, Silvia Solana, Maria José Torres, Pascual|||0000-0001-7903-3478 Juanes, Alba Quibus, Laura Ruiz, Emilio Sanpedro, Eduardo Quirant, Bibiana|||0000-0002-3875-8074 Martínez Cáceres, Eva María|||0000-0002-6762-8025 Ramo-Tello, Cristina|||0000-0001-8643-5053 Presas Rodríguez, Sílvia|||0000-0001-8545-2476 García Rubio, Sebatián Baron, Beatriz Pardiñas|||0000-0002-3041-9238 Ramió-Torrentà, Lluís|||0000-0002-6999-1004 Sotoca Fernández, Javier|||0000-0003-3400-1434 González-Suárez, Inés|||0000-0002-9897-0771 Eichau Madueño, Sara Prieto, Jose Maria|||0000-0002-8170-0724 Blasco Quilez, Maria Rosario|||0000-0003-2719-4629 Sabín-Muñoz, Julia|||0000-0001-5745-7544 Sánchez López, Antonio José|||0000-0001-7168-6175 Llorens Calatayud, Gloria Calles, Carmen Perez-Sempere, Angel|||0000-0002-0195-2834 Garces, Moises|||0000-0002-1756-5492 Carmona, Olga|||0000-0002-5957-0046 Moral, Ester Hervás, José Vicente Blanco, Yolanda Sola-Valls, Nuria Téllez Lara, Nieves|||0000-0001-8787-2239 Forero, Lucía|||0000-0003-0256-6748 Brieva Ruiz, Luis|||0000-0002-5871-6189 |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Multiple Sclerosis COVID-19 SARS-CoV-2 DMT Seroprevalence |
| topic |
Multiple Sclerosis COVID-19 SARS-CoV-2 DMT Seroprevalence |
| description |
Background: The EMCOVID project conducted a multi-centre cohort study to investigate the impact of COVID-19 on patients with Multiple Sclerosis (pwMS) receiving disease-modifying therapies (DMTs). The study aimed to evaluate the seroprevalence and persistence of SARS-CoV-2 antibodies in MS patients enrolled in the EMCOVID database. The DMTs were used to manage MS by reducing relapses, lesion accumulation, and disability progression. However, concerns arose regarding the susceptibility of pwMS to COVID-19 due to potential interactions between SARS-CoV-2 and the immune system, as well as the immunomodulatory effects of DMTs. Methods: This prospective observational study utilized data from a Multiple Sclerosis and COVID-19 (EMCOVID-19) study. Demographic characteristics, MS history, laboratory data, SARS-CoV-2 serology, and symptoms of COVID-19 were extracted for pwMS receiving any type of DMT. The relationship between demographics, MS phenotype, DMTs, and COVID-19 was evaluated. The evolution of SARS-CoV-2 antibodies over a 6-month period was also assessed. Results: The study included 709 pwMS, with 376 patients providing samples at the 6-month follow-up visit. The seroprevalence of SARS-CoV-2 antibodies was higher among pwMS than the general population, with Interferon treatment being significantly associated with greater seroprevalence (16.9% vs. 8.4%; p 0.003). However, no other specific DMT showed a significant association with antibody presence. A total of 32 patients (8.5%) tested positive for IgG, IgM, or IgA antibodies against SARS-CoV-2 at baseline, but then tested negative at 6 months. Most of the pwMS in the cohort were asymptomatic for COVID-19 and, even among symptomatic cases, the prognosis was generally favourable. Conclusion: pwMS undergoing DMTs exhibited a higher seroprevalence of COVID-19 than the general population. Interferon treatment was associated with a higher seroprevalence, suggesting a more robust humoral response. This study provides valuable insights into the seroprevalence and persistence of SARS-CoV-2 antibodies in pwMS and contributes to our understanding of the impact of COVID-19 amongst this population. |
| publishDate |
2023 |
| dc.date.none.fl_str_mv |
2 2023-01-01 2023 2023-01-01 |
| dc.type.none.fl_str_mv |
Article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://ddd.uab.cat/record/310697 https://dx.doi.org/urn:doi:10.3390/jcm12237243 |
| url |
https://ddd.uab.cat/record/310697 https://dx.doi.org/urn:doi:10.3390/jcm12237243 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.relation.none.fl_str_mv |
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 COV20/00948 |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona |
| instname_str |
Universitat Autònoma de Barcelona |
| reponame_str |
Dipòsit Digital de Documents de la UAB |
| collection |
Dipòsit Digital de Documents de la UAB |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869411079424049152 |
| spelling |
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying TherapiesA Multi-Centre StudySancho-Saldaña, AgustínGil Sánchez, Anna|||0000-0002-0738-5578González-Mingot, Cristina|||0000-0002-6387-8764Peralta, SilviaSolana, Maria JoséTorres, Pascual|||0000-0001-7903-3478Juanes, AlbaQuibus, LauraRuiz, EmilioSanpedro, EduardoQuirant, Bibiana|||0000-0002-3875-8074Martínez Cáceres, Eva María|||0000-0002-6762-8025Ramo-Tello, Cristina|||0000-0001-8643-5053Presas Rodríguez, Sílvia|||0000-0001-8545-2476García Rubio, SebatiánBaron, Beatriz Pardiñas|||0000-0002-3041-9238Ramió-Torrentà, Lluís|||0000-0002-6999-1004Sotoca Fernández, Javier|||0000-0003-3400-1434González-Suárez, Inés|||0000-0002-9897-0771Eichau Madueño, SaraPrieto, Jose Maria|||0000-0002-8170-0724Blasco Quilez, Maria Rosario|||0000-0003-2719-4629Sabín-Muñoz, Julia|||0000-0001-5745-7544Sánchez López, Antonio José|||0000-0001-7168-6175Llorens Calatayud, GloriaCalles, CarmenPerez-Sempere, Angel|||0000-0002-0195-2834Garces, Moises|||0000-0002-1756-5492Carmona, Olga|||0000-0002-5957-0046Moral, EsterHervás, José VicenteBlanco, YolandaSola-Valls, NuriaTéllez Lara, Nieves|||0000-0001-8787-2239Forero, Lucía|||0000-0003-0256-6748Brieva Ruiz, Luis|||0000-0002-5871-6189Multiple SclerosisCOVID-19SARS-CoV-2DMTSeroprevalenceBackground: The EMCOVID project conducted a multi-centre cohort study to investigate the impact of COVID-19 on patients with Multiple Sclerosis (pwMS) receiving disease-modifying therapies (DMTs). The study aimed to evaluate the seroprevalence and persistence of SARS-CoV-2 antibodies in MS patients enrolled in the EMCOVID database. The DMTs were used to manage MS by reducing relapses, lesion accumulation, and disability progression. However, concerns arose regarding the susceptibility of pwMS to COVID-19 due to potential interactions between SARS-CoV-2 and the immune system, as well as the immunomodulatory effects of DMTs. Methods: This prospective observational study utilized data from a Multiple Sclerosis and COVID-19 (EMCOVID-19) study. Demographic characteristics, MS history, laboratory data, SARS-CoV-2 serology, and symptoms of COVID-19 were extracted for pwMS receiving any type of DMT. The relationship between demographics, MS phenotype, DMTs, and COVID-19 was evaluated. The evolution of SARS-CoV-2 antibodies over a 6-month period was also assessed. Results: The study included 709 pwMS, with 376 patients providing samples at the 6-month follow-up visit. The seroprevalence of SARS-CoV-2 antibodies was higher among pwMS than the general population, with Interferon treatment being significantly associated with greater seroprevalence (16.9% vs. 8.4%; p 0.003). However, no other specific DMT showed a significant association with antibody presence. A total of 32 patients (8.5%) tested positive for IgG, IgM, or IgA antibodies against SARS-CoV-2 at baseline, but then tested negative at 6 months. Most of the pwMS in the cohort were asymptomatic for COVID-19 and, even among symptomatic cases, the prognosis was generally favourable. Conclusion: pwMS undergoing DMTs exhibited a higher seroprevalence of COVID-19 than the general population. Interferon treatment was associated with a higher seroprevalence, suggesting a more robust humoral response. This study provides valuable insights into the seroprevalence and persistence of SARS-CoV-2 antibodies in pwMS and contributes to our understanding of the impact of COVID-19 amongst this population. 22023-01-0120232023-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/310697https://dx.doi.org/urn:doi:10.3390/jcm12237243reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengInstituto de Salud Carlos III https://doi.org/10.13039/501100004587 COV20/00948open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3106972026-06-06T12:50:31Z |
| score |
15,811543 |